The use of olaparib in the treatment of HER2-negative breast cancer with mutations in BRCA genes

To date, the incidence and mortality from breast cancer is at a consistently high level both in the Russian Federation and in other countries. Due to the variability in the expression of estrogen receptors, progesterone, human epidermal growth factor 2 (HER-2) by breast tumor cells, pharmacotherapeutic treatment tactics will be different. To increase patient survival and reduce tumor progression, different treatment approaches are used depending on the tumor phenotype. In particular, PARP (poly(ADP-ribose) inhibitors are used for pharmacotherapy of breast cancer with HER2-negative status associated with mutations in BRCA genes-polymerase). One of the representatives of this group, olaparib, affects cells with defects in the BRCA1/2 genes, leading to the accumulation of replication errors and the death of tumor cells. This article provides an overview of the evidence-based clinical studies of the use of Olaparib in the treatment of breast cancer with HER2-negative status and associated with mutations in the BRCA1 and BRCA2 genes.